title: Diltiazem prevents hypertrophy progression, preserves systolic function, and normalises myocardial oxygen utilisation in the spontaneously hypertensive rat.
abstract: The effects of diltiazem, a calcium channel blocker, and methyldopa, an adrenergic blocker, on left ventricular hypertrophy and left ventricular function were assessed in spontaneously hypertensive rats and Wistar-Kyoto controls. Diltiazem (30 mg.kg-1/day), methyldopa (400 mg.kg-1/day), or placebo were given with water for six months. Left ventricular function was studied in 12 month old animals using an isovolumetrically contracting heart preparation by measuring maximum developed pressure and myocardial oxygen consumption. Systolic blood pressure was reduced by both drugs but more so by methyldopa. Despite its lesser antihypertensive effect, diltiazem reduced heart to body weight ratios in the spontaneously hypertensive rat to a similar degree as methyldopa (3.4(0.2) and 3.4(0.1) compared with placebo 3.7(0.2), p less than 0.05). Maximum developed pressure increased with methyldopa and diltiazem compared with placebo (188(11) and 200(11) vs 166(11) mmHg, p less than 0.05). Myocardial oxygen consumption was lower in the spontaneously hypertensive rat receiving placebo than in the controls (22.8(3.2) vs 28.3(3.8) ml.min-1.100 g-1, p less than 0.05) and was significantly increased by diltiazem but not by methyldopa (27.9(0.4) vs 24.5(0.6) ml.min-1.100 g-1, p less than 0.05 and NS respectively vs the spontaneously hypertensive rat receiving placebo). Diltiazem and methyldopa normalised the isomyosin composition in the spontaneously hypertensive rat. Myocardial concentrations of energy related metabolites obtained at maximum developed pressure were not different between spontaneously hypertensive rats receiving placebo and controls. However, both diltiazem and methyldopa treated spontaneously hypertensive rats showed a significant reduction in adenosine triphosphate and phosphocreatine and a rise in inorganic phosphate.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cardiovascular Research Institute, University of California School of Medicine and Pharmacy, San Francisco.
authors.forename: J F
authors.initials: JF
authors.lastname: Tubau
authors.forename: J
authors.initials: J
authors.lastname: Wikman-Coffelt
authors.forename: B M
authors.initials: BM
authors.lastname: Massie
authors.forename: J
authors.initials: J
authors.lastname: Szlachcic
authors.forename: W W
authors.initials: WW
authors.lastname: Parmley
authors.forename: R
authors.initials: R
authors.lastname: Sievers
authors.forename: S
authors.initials: S
authors.lastname: Henderson
mesh_terms: D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy* / Q000209:etiology; D003326:Coronary Circulation / Q000187:drug effects; D004110:Diltiazem / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects*; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D066298:In Vitro Techniques; D008750:Methyldopa / Q000627:therapeutic use; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009218:Myosins / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013599:Systole / Q000187:drug effects
chemical_list: D008750:Methyldopa; D009218:Myosins; D004110:Diltiazem